Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Imagion Biosystems Ltd. Business Overview & Revenue Model
Imagion Biosystems Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.67M | 1.37M | 473.43K | 232.87K | 205.72K |
| Gross Profit | 2.26M | -3.88M | -3.14M | -2.47M | -2.66M |
| EBITDA | -700.09K | -10.30M | -9.49M | -5.90M | -5.19M |
| Net Income | -2.07M | -12.47M | -9.81M | -8.64M | -7.80M |
Balance Sheet | |||||
| Total Assets | 2.80M | 4.59M | 9.98M | 14.12M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 2.67M | 227.08K | 4.45M | 13.39M | 13.20M |
| Total Debt | 2.85M | 6.04M | 4.60M | 46.02K | 660.98K |
| Total Liabilities | 5.09M | 8.37M | 5.30M | 809.88K | 1.21M |
| Stockholders Equity | -2.28M | -3.79M | 4.68M | 13.31M | 12.91M |
Cash Flow | |||||
| Free Cash Flow | -1.27M | -8.51M | -9.21M | -5.29M | -4.63M |
| Operating Cash Flow | -1.27M | -8.32M | -8.70M | -5.07M | -4.62M |
| Investing Cash Flow | 83.74K | -190.38K | -468.73K | -310.09K | -7.86K |
| Financing Cash Flow | 3.61M | 4.29M | -962.06K | 5.15M | 14.52M |
Imagion Biosystems Ltd. Technical Analysis
Imagion Biosystems Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$36.61M | 20.00 | 87.09% | 9.33% | 1.86% | 16.10% | |
52 Neutral | AU$51.65M | ― | -51.49% | ― | 80.84% | 57.59% | |
52 Neutral | $7.58B | 0.48 | -62.71% | 2.36% | 15.33% | 0.41% | |
47 Neutral | AU$3.22M | ― | ― | 55.07% | 88.20% | ||
45 Neutral | AU$24.52M | ― | -104.23% | ― | ― | -17.26% | |
45 Neutral | AU$40.75M | ― | -39.07% | ― | 26.07% | 0.85% |
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Ltd. has announced the issuance of 1,200,000 unquoted equity securities under an employee incentive scheme, set to expire in May 2030. This move is part of the company’s strategy to incentivize and retain key personnel, potentially impacting its operational dynamics and market positioning by aligning employee interests with long-term company performance.
Imagion Biosystems Ltd. has made significant progress in its MagSense® HER2 breast cancer imaging agent program, aiming to file an Investigational New Drug (IND) application for a Phase 2 clinical trial with the FDA in the third quarter of 2025. The company received positive feedback from the FDA, boosting confidence in the IND submission. Additionally, Imagion has entered into a Master Service Agreement with Biosensis Ltd. to manage costs and advance nanoparticle research, and appointed Dr. Leonardo Kayat-Bittencourt as a clinical advisor for its prostate cancer program. The company is also preparing for the manufacturing of the MagSense® HER2 imaging agent and has selected Dr. William Dooley as the Principal Investigator for the upcoming study. Financially, Imagion reported a decrease in cash balance and operating cash outflows, with plans to reduce corporate costs and focus funds on the IND application.
Imagion Biosystems has announced a correction regarding the exercise price and expiry date of a tranche of options. The corrected exercise price is $0.019, and the expiry date is 29 May 2028. This update reflects an administrative error and is crucial for stakeholders to note as it impacts the company’s financial instruments and potentially its market positioning.
Imagion Biosystems Ltd. has announced a change in the director’s interest, with Robert Romeo Proulx acquiring 2,000,000 unlisted options. This development reflects a strategic move within the company’s leadership, potentially impacting its operational focus and signaling confidence in its future growth prospects. Stakeholders may view this as a positive indicator of the company’s commitment to enhancing its market position and achieving its long-term objectives.
Imagion Biosystems Ltd. announced the issuance of 1,500,000 unquoted equity securities under an employee incentive scheme, set to expire on May 29, 2030, with an exercise price of $0.012. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational dynamics and aligning staff interests with long-term company performance.
Imagion Biosystems Ltd. has announced the issuance of 4 million unquoted equity securities in the form of options, set to expire on May 29, 2030, with exercise prices of $0.024 and $0.012. This move is part of an employee incentive scheme and reflects the company’s strategy to enhance its operational capabilities and retain key talent, potentially strengthening its market position in the biotechnology sector.
Imagion Biosystems has received positive feedback from the FDA regarding its planned Phase 2 clinical trial for the MagSense® HER2 imaging agent, intended for early detection of HER2 breast cancer. This feedback is a significant step in the regulatory process, allowing the company to proceed confidently with the formal submission of an Investigational New Drug application, expected in the third quarter of 2025, which could enhance its market positioning and stakeholder confidence.
Imagion Biosystems announced its participation in the Landmark Venture Forum, a prestigious event limited to select investors and guests. The company’s Chief Business Officer, Ward Detwiler, will present on their groundbreaking molecular magnetic resonance imaging technology, which could significantly impact the early detection of cancer, potentially improving Imagion’s industry positioning and offering promising implications for stakeholders.
Imagion Biosystems has announced a change in its registered office and principal place of business to a new address in Melbourne, while maintaining the same contact details. This move signifies a strategic step in its operations, potentially enhancing its business functions and stakeholder engagement.
Imagion Biosystems Ltd. announced the results of its Annual General Meeting held on May 30, 2025, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of Brett Mitchell as a director, and the approval of options issuance to key personnel and entities. The successful passage of these resolutions reflects shareholder support for the company’s strategic direction and governance, potentially strengthening its market position and operational capabilities.
Imagion Biosystems has provided a business update ahead of its Annual General Meeting, highlighting the progress of its MagSense® HER2 Imaging Agent for HER2+ breast cancer. The company plans to begin manufacturing the imaging agent in June and aims to file an Investigational New Drug application with the FDA for a Phase 2 study in the third quarter of 2025. The company has engaged with the FDA for feedback and identified a Principal Investigator for the study. Additionally, Imagion is optimizing MRI protocols in collaboration with Siemens and Wayne State University. The company is also preparing to restart its prostate and ovarian cancer programs, with Dr. Kayat-Bittencourt joining as a clinical advisor for the prostate cancer program.
Imagion Biosystems Limited has announced that its Annual General Meeting (AGM) will be held virtually on May 30, 2025. Shareholders are encouraged to access meeting materials online and submit their proxy votes ahead of the meeting. The virtual format allows shareholders to participate by asking questions and voting on resolutions, ensuring engagement despite the lack of a physical gathering.
Imagion Biosystems has released its quarterly activity report for Q1 FY2025, highlighting progress in its MagSense® HER2 breast cancer imaging agent program. The company is preparing to file an Investigational New Drug (IND) application with the U.S. FDA, which would enable the next phase of clinical studies. Manufacturing of the imaging agent is underway, and discussions with leading hospitals and cancer centers in the U.S. are ongoing. The company expects to file the IND in the third quarter and begin the Phase 2 study in the latter half of the year. Additionally, research and development for prostate and ovarian cancer programs are anticipated to commence later in the year, contingent on funding. The company reported a cash balance of AU$1.71 million at the end of March 2025, with increased operating cash outflows due to R&D expenditures.